Ober Scharrer Group (“OSG”) is a leading provider of outpatient treatment for major causes of blindness and visual impairment, offering diagnosis as well as surgical and non-invasive treatment of eye disorders in c. 80 locations across Germany.

OSG, founded in 1982, is a recognised innovator in the field of ophthalmology, providing state-of-the-art medical care of the highest quality to both public and private patients. The Group specialises in eye surgeries such as cataract operations and Intravitreal Operative Medication (IVOM) application for degenerative eye disorders, with more than 90,000 surgical procedures performed annually. In addition, OSG offers diagnostic and non-invasive treatments, catering to the wellbeing of over 500,000 patients every year.  

Nordic Capital Fund IX acquired OSG in April 2018. The ambition is to support the further development of OSG in line with its current strategy of providing innovative medical care of the highest quality.

Key Information

Revenues Icon

Revenues 2017

EUR 110 million

Employees Icon

Employees

680

Ownership Icon

Ownership

Nordic Capital Fund IX, controlling shareholding

Head Office Icon

Head office

Fürth, Germany

Investment Icon

Investment date

2018